Canada markets closed
  • S&P/TSX

    21,125.90
    -487.28 (-2.25%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • DOW

    34,899.34
    -905.04 (-2.53%)
     
  • CAD/USD

    0.7819
    -0.0086 (-1.09%)
     
  • CRUDE OIL

    68.15
    -10.24 (-13.06%)
     
  • BTC-CAD

    70,475.27
    -272.84 (-0.39%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • GOLD FUTURES

    1,785.50
    +1.20 (+0.07%)
     
  • RUSSELL 2000

    2,245.94
    -85.52 (-3.67%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • NASDAQ

    15,491.66
    -353.57 (-2.23%)
     
  • VOLATILITY

    28.62
    +10.04 (+54.04%)
     
  • FTSE

    7,044.03
    -266.34 (-3.64%)
     
  • NIKKEI 225

    28,751.62
    -747.66 (-2.53%)
     
  • CAD/EUR

    0.6905
    -0.0143 (-2.03%)
     

What Type Of Shareholders Make Up e-therapeutics plc's (LON:ETX) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in e-therapeutics plc (LON:ETX) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

e-therapeutics is not a large company by global standards. It has a market capitalization of UK£203m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about e-therapeutics.

See our latest analysis for e-therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About e-therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that e-therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at e-therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in e-therapeutics. Looking at our data, we can see that the largest shareholder is Richard Griffiths with 24% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.8% and 9.6% of the stock. Ahmad Mortazavi, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

On looking further, we found that 50% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

Insider Ownership Of e-therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

It seems insiders own a significant proportion of e-therapeutics plc. Insiders own UK£94m worth of shares in the UK£203m company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

General Public Ownership

With a 16% ownership, the general public have some degree of sway over e-therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Company Ownership

We can see that Private Companies own 7.3%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that e-therapeutics is showing 3 warning signs in our investment analysis , you should know about...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting